Aurobindo Pharma Sees Sharp Open Interest Surge Amid Bearish Price Action

Open Interest and Volume Dynamics

On 10 February 2026, Aurobindo Pharma’s open interest (OI) in derivatives rose sharply to 64,459 contracts from the previous 53,826, marking an increase of 10,633 contracts or 19.75%. This expansion in OI was accompanied by a robust volume of 95,816 contracts traded, indicating active participation from market players. The futures segment alone accounted for a value of approximately ₹80,218 lakhs, while the options segment’s notional value was substantially higher at ₹56,037 crores, culminating in a total derivatives value of ₹90,510 lakhs.

The underlying stock price closed at ₹1,144, having declined by 5.31% on the day, underperforming its sector by nearly 5% and the broader Sensex by 5.52%. Intraday, the stock touched a low of ₹1,137.8, with the weighted average price skewed towards the lower end of the day’s range, signalling selling pressure.

Market Positioning and Sentiment

The simultaneous rise in open interest and decline in price typically points to fresh short positions being established or existing shorts being augmented. This is further corroborated by the stock trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a bearish technical setup. The delivery volume on 9 February was 3.98 lakh shares, down 39.02% from the five-day average, suggesting waning long-term investor conviction amid the recent price slide.

Such a pattern often reflects a market consensus leaning towards a downward correction or consolidation phase, with traders positioning for further downside or volatility. The sizeable increase in open interest, despite falling prices, implies that new money is flowing into bearish bets rather than profit-taking by longs.

Technical and Fundamental Context

Aurobindo Pharma, a mid-cap pharmaceutical and biotechnology company with a market capitalisation of ₹70,172 crores, currently holds a Mojo Score of 68.0 and a Mojo Grade of Hold, downgraded from Buy as of 1 December 2025. The downgrade reflects a reassessment of the stock’s risk-reward profile amid recent volatility and sector headwinds.

The stock’s underperformance relative to its sector and the broader market, combined with the negative price momentum and declining investor participation, suggests caution. The liquidity profile remains adequate, with the stock capable of handling trade sizes up to ₹3.71 crores based on 2% of the five-day average traded value, ensuring that institutional activity is feasible without excessive price impact.

Implications for Investors and Traders

The surge in open interest alongside falling prices is a classic indicator of increased bearish positioning. Traders should be wary of potential further downside or heightened volatility in the near term. The stock’s failure to hold above key moving averages and the drop in delivery volumes indicate that long-term holders may be reducing exposure, while short-term traders are likely increasing their bets on a decline.

However, the sizeable derivatives activity also suggests that the market is actively pricing in upcoming events or earnings announcements, which could act as catalysts for directional moves. Investors should monitor changes in open interest and volume patterns closely, alongside fundamental developments, to gauge evolving market sentiment.

Sector and Broader Market Comparison

While Aurobindo Pharma declined by 5.31% on the day, the Pharmaceuticals & Biotechnology sector was largely flat, registering a marginal loss of 0.06%, and the Sensex gained 0.21%. This relative underperformance highlights company-specific pressures or profit-taking that are not reflective of the broader industry or market trends.

Given the sector’s generally stable performance, the sharp increase in derivatives open interest for Aurobindo Pharma may also indicate speculative positioning or hedging activity by institutional investors anticipating near-term volatility or event risk.

Outlook and Strategic Considerations

Investors should approach Aurobindo Pharma with caution in the current environment. The Hold rating and Mojo Score of 68.0 reflect a neutral stance, balancing the company’s strong fundamentals against recent technical weakness and market uncertainty. The increased open interest signals that the derivatives market is actively positioning for potential price swings, which could present trading opportunities for nimble investors but also heightened risk for long-term holders.

Monitoring upcoming corporate announcements, earnings releases, and sector developments will be crucial to reassessing the stock’s outlook. Additionally, tracking changes in open interest and volume in the derivatives segment can provide early signals of shifts in market sentiment and positioning.

Summary

Aurobindo Pharma’s derivatives market activity has intensified with a near 20% jump in open interest amid a 5.31% drop in the underlying stock price. This divergence suggests increased bearish bets and a cautious market stance. The stock’s technical indicators remain weak, and investor participation is declining, reinforcing the Hold rating. While the sector remains stable, company-specific factors are driving volatility. Investors should remain vigilant and consider alternative opportunities within the Pharmaceuticals & Biotechnology space.

Unlock special upgrade rates for a limited period. Start Saving Now →